Brexucabtagen-Autoleucel

From Medicine GPT
Jump to navigation Jump to search
Brexucabtagen-Autoleucel
TermBrexucabtagen-Autoleucel
Short definitionBrexucabtagen-Autoleucel - (pronounced) (brek-suh-KAB-tuh-jeen aw-toh-LOO-sel) A drug used to treat adults with mantle cell lymphoma or B-cell acute lymphoblastic leukemia that has come back or has not improved after other treatment. It is also being studied in the treatment of other types of cancer. 
TypeCancer terms
SpecialtyOncology
LanguageEnglish
SourceNCI
Comments


Brexucabtagen-Autoleucel - (pronounced) (brek-suh-KAB-tuh-jeen aw-toh-LOO-sel) A drug used to treat adults with mantle cell lymphoma or B-cell acute lymphoblastic leukemia that has come back or has not improved after other treatment. It is also being studied in the treatment of other types of cancer. Brexucabtagene-Autoleucel is made using a patient's T cells (a type of cell in the immune system). A gene for a special receptor called the chimeric antigen receptor (CAR) is added to the T cells in the laboratory. Large numbers of these modified T cells, known as CAR T cells, are cultivated in the laboratory and given to the patient by infusion. Brexucabtagene autoleucel attaches to a protein called CD19, which is found on some lymphoma cells and leukemia cells. This helps the body's immune system kill cancer cells. Brexucabtagene Autoleucel is a form of CAR T cell therapy. Also called Tecartus

External links

Esculaap.svg

This MedicineGPT article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski